Fremanezumab
Unchecked
Anti-CGRP ligand monoclonal antibody
Fremanezumab
Ajovy
Fremanezumab (brand name Ajovy) is an anti-CGRP monoclonal antibody approved in 2018 for migraine prevention. It is unique in offering both monthly and quarterly dosing options.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-CGRP ligand monoclonal antibody
Common uses
Preventive treatment of migraine in adults (episodic and chronic)
Pharmacy
Starting dose
225 mg SC monthly, or 675 mg SC every 3 months (quarterly)
Preparations
225 mg/1.5 mL prefilled syringe or autoinjector
US FDA Max
675 mg/quarter
Pharmacology
Routes
Subcutaneous
Onset
Over weeks
Duration
Monthly or quarterly dosing
Half-life
~31 days
Bioavailability
Not formally established
Pregnancy
Limited data; avoid
Legal status
Rx
Purported mechanism
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide